moving from semaglutide to tirzepatide Transition: Clinical Dosing Guide – PlexusDx Transitioning Treatments: What to Expect

The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons

J Clin Pathol (2005) 58:112632

The hazard ratio increased with longer exposure to GLP-1 receptor agonists, rising to more than three times as high for patients exposed for longer than 30 months vs

Abasheva, D., Ortiz, A., & Fernandez-Fernandez, B

Cravings Crushed